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Abstract
Introduction: Sleep-related breathing disorders (SRBD) are commonly present in patients with Prader-Willi syndrome (PWS). Recom-
binant human growth hormone (rhGH) treatment is reported to improve breathing function in PWS, but the findings are not explicit. 
Material and methods: Screening polysomnography-polygraphy (PSG), assessing nasal respiratory flow, respiratory effort, and blood 
oxygen saturation, was used. Group 1 — before rhGH therapy (n = 11, mean age 3.0 years); PSG was repeated after the start of rhGH 
therapy in a mean time of 0.9 years in six patients (Group 1a). Group 2 — on rhGH treatment, for a mean time of four years (n = 17, mean 
age 8.8 years). Group 3 — without rhGH therapy due to severe obesity (n = 8, mean age 13.1 years). 
Results: Group 1 — mean apnoea-hypopnoea index (AHI) was 10.2, oxygen desaturation index (ODI) — 36.3, Group 1a — AHI 12.0, 
ODI 60.9, Group 2 — AHI 9.0, ODI 25.1, Group 3 — AHI 8.2, ODI 22.0. ODI was significantly higher in Group 1a than in the other groups 
(p < 0.005), but not strictly related to SRBD. The results in Group 2 did not differ significantly from those of Group 1.
Conclusions: Our study proves the high frequency of SRBD among PWS patients, with worsening of ODI after short-term rhGH therapy. 
(Endokrynol Pol 2017; 68 (6): 676–680)
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Streszczenie
Wstęp: Zaburzenia oddychania w czasie snu (sleep-related breathing disorders, SRBD) występują często u pacjentów z zespołem Pradera-
-Willego (PWS). Opisywana jest poprawa funkcji oddechowych w trakcie leczenia preparatem ludzkiego rekombinowanego hormonu 
wzrostu (GH), jednak dane te nie są jednoznaczne.
Materiał i metody: Przesiewowa ocena polisomnograficzna — poligrafia (PSG), oceniająca przepływ powietrza w trakcie oddychania, 
wysiłek oddechowy, saturację. Grupa 1 — przed leczeniem GH (n = 11, średni wiek 3 lata); PSG powtórzono po rozpoczęciu leczenia GH 
średnio po 0,9 roku u 6 pacjentów (grupa 1a). Grupa 2 — w trakcie leczenia GH, średni czas terapii 4 lata (n = 17, średni wiek 8,8 roku). 
Grupa 3 — bez leczenia GH z powodu znacznej otyłości (n = 8, średni wiek 13,1 roku). 
Wyniki: Grupa 1 — średni wskaźnik bezdech-spłycenie oddychania (apnea-hypopnea index, AHI) wynosił 10,2, wskaźnik desaturacji (oxygen 
desaturation index, ODI) — 36,3, group 1a — AHI 12,0, ODI 60,9, group 2 — AHI 9,0, ODI 25,1, group 3 — AHI 8,2, ODI 22,0. 
ODI było znacząco wyższe w grupie 1a w porównaniu do pozostałych grup (p < 0,005), ale nie wykazywało ścisłego związku z pozosta-
łymi wskaźnikami SRDB. Porównanie wyników grupy 2 i grupy 1 nie wykazało różnic istotnych statystycznie. 
Wnioski: Przedstawione wyniki potwierdzają wysoką częstość występowania SRBD u pacjentów PWS, z istotnym pogorszeniem ODI 
po krótkim okresie leczenia GH. (Endokrynol Pol 2017; 68 (6): 676–680)
Słowa kluczowe: zaburzenia oddychania w czasie snu, zespół Pradera-Willego, leczenie hormonem wzrostu
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Introduction
Prader-Willi syndrome (PWS) is the first recognised 
human genetic imprinting disorder. The main clinical 
features of PWS are hypotonia, psychomotor delay, dif-
ficulties in feeding during the first year of life, followed 
by lack of satiety and obesity developing from the early 
childhood, hypogonadotropin hypogonadism, short 
stature, and cognitive and behavioural dysfunction [1]. 
It is well documented that sleep-related breathing 
disorders (SRBD), both central apnoea (CA) and ob-
structive sleep apnoea (OSA), are commonly present in 
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PWS patients. OSA is caused by several factors, such as: 
obesity, narrowing of upper airways and reduction of 
saliva excretion, adenoid/tonsillar hypertrophy, hypo-
tonic breathing muscles, or scoliosis. CA might be caused 
by hypothalamic dysfunction [2]. Moreover, defensive 
mechanisms of circulatory and respiratory systems 
during development of hypoxia and hypercapnia are 
defective in PWS. Breathing disorders may negatively 
influence both physical and psychological wellbeing and 
social performance of PWS patients. They may also have 
impact on a shorter life expectancy result in PWS [3, 4]. 
Recombinant human growth hormone (rhGH) treat-
ment has been reported to improve breathing function 
in PWS, mainly through the improvement of body 
composition and muscle strength, which may positively 
influence obstructive breathing disorders. However, the 
findings are not explicit [5–8]. Some data suggest that the 
first period of rhGH therapy can worsen SRBD [9, 10]. 
The hypothesis includes the possibility of adenoid 
enlargement due to high insulin-like growth factor 1 
(IGF1) levels after the rhGH initiation [9]. 
SRBD can be assessed by polysomnography stud-
ies (PSG). Screening polysomnography, also called 
polygraphy, includes assessment of respiratory flow, 
respiratory effort, and blood oxygen [11]. 
Classification of respiratory events in children 
according to the American Academy of Sleep Medi-
cine (AASM) includes apnoea and hypopnoea rules 
[12–14]. The American Academy of Paediatrics (AAP) 
published clinical practice guidelines regarding ob-
structive sleep apnoea syndrome (OSAS) in children, 
in 2012 [15]. The normative values of polysomnogra-
phy in children and adolescents are also included in 
a paper by Uliel in Chest 2004 [16]. The normal value 
for apnoea-hypopnoea index (AHI) is < 1/hr. Mild 
AHI is scored when the value is between 1 and 5/hr, 
moderate AHI is between 5 and 10/hr and severe AHI 
is more than 10/hr. Desaturation value is scored as 
≥ 4%, minimal normal O2 saturation as 92%. There is 
a range of various oxygen desaturation indexes (ODI) 
both in children and in adults. The British Thoracic 
Society defines normal ODI as < 15 desaturations of 
4%/hr, other studies criteria show the normal to mild 
ODI values as ≤ 15 desaturations of 3%/hr [17]. The 
desaturation value in children is mainly scored as 
≥ 3%, the normal range of ODI criteria in the paediatric 
population was also published as < 2.6 desaturations 
of 4%/hr [18–21]. 
The main aims of our study were to determine the 
frequency and specify the type of SRBD in our group 
of PWS patients, to analyse the influence of rhGH 
treatment on SRBD, and to compare the PSG results of 
rhGH-treated children and severely obese, non-treated 
PWS patients.
Material and methods
We present the PSG results in 36 PWS patients who were 
divided into three groups: before (Group 1) and after ini-
tiating rhGH treatment (Group 1a), on rhGH treatment 
for a mean time 4 ± 3.0 years (Group 2) and patients 
not treated with rhGH due to severe obesity (Group 3). 
PSG was performed with Porti 6, as polygraphy, 
assessing nasal respiratory flow, respiratory effort by 
thoracic and abdominal strain gauges, and blood oxy-
gen saturation using a pulse oximeter that allowed de-
termination of AHI and differentiation of CA and OSA. 
All patients had assessment by an ENT physician (ear 
nose and throat specialist). The patients diagnosed with 
adenotonsillar hypertrophy had no surgery procedure 
prior to the sleep studies. Body mass index (BMI) was 
calculated as body weight (kilograms)/height (square 
metres) and expressed as Z-score according to the Po-
lish national charts [22]. 
PSG was assessed by an experienced sleep specialist 
(MJ) according to the AASM rules. The study protocol 
was approved by the Ethical Committee of the Chil-
dren’s Memorial Health Institute. Written, informed 
consent was obtained from the patients’ parents. The 
study was sponsored by the Children’s Memorial 
Health Institute, grant number S108/2009.
Statistical analyses were performed using statistical 
software Statistica version 6.0. Results are expressed 
as mean values and standard deviations (± SD). 
Para meters were evaluated with t-Student test for 
independent samples and paired t-Student test for 
parameters before and after short-term GH treatment. 
Correlations between the assessed parameters were 
evaluated with r-Pearson correlation and r-Spearman 
rank correlation depending on the type of distribution. 
P values < 0.05 were considered statistically significant.
Some of the data were excluded from the analysis 
because the results were technically unreliable. We had 
to exclude the AHI and ODI results of one patient from 
Group 1 and the ODI results of two patients from Group 2. 
Results
Group 1 — patients before rhGH treatment 
Eleven children: six girls and five boys, mean age 
3.0 years (± 3.0), genotype: deletion of chromosome 
15q11-13 in seven patients, abnormality in methylation 
pattern, with an unidentified underlying genetic defect 
in four patients. Patients were mostly non-obese, mean 
BMI SDS 0.2 (± 2.3). Two patients had BMI SDS > 2 
(4.9 and 3.5) and had not started rhGH therapy at that 
time. Mean IGF1 SDS was –0.9 (± 0.4). 
Clinical characteristics are shown in Table I. Mean AHI 
was 10.2 (± 6.9), AI — 6 (± 4.5), HI — 4.2 (± 2.9) (Table II). 
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Index of CA was 2.4 (± 3.1), OSA 2.3 (± 1.2), mixed ap-
noea 1.3 (± 1.2) (Table III). Mean ODI was 36.3 (± 19.2). 
Other desaturation characteristics are shown in Table IV.
The AHI in one patient with adenoid enlargement 
and obesity was scored as severe (AHI 19.4). One patient 
with laryngeal laxity and scoliosis had also severe SRBD, 
AHI 13.9 with Cheyne-Stokes respiration episodes.
Group 1a — six patients after short-term rhGH 
therapy
rhGH therapy was started in six patients from Group 1: 
four girls and two boys. Mean age of the patients was 
2.5 years (± 0.8), mean BMI SDS — 0.1 (± 2.3). PSG was 
repeated after the initiation of rhGH therapy in mean 
time 0.9 years (± 0.7). Mean rhGH dose was 0.024 mg/kg/ 
/day (± 0.004), growth velocity 10.6 cm/yr (± 3.7), mean 
IGF1 SDS 0.2 (± 1.2). The values of PSG were: AHI 12 
(± 5.8), AI 9.1 (± 4.7), HI 2.9 (± 2.5) (Table II). CA was 4.8 
(± 2.9), while OSA was 2.7 (± 1.7) and mixed apnoea in-
dex was 1.6 (± 1.8) (Table III). The only value that reached 
the statistical significance in comparison to Group 1 was 
ODI: mean ODI 60.9 (± 25.4) vs. 36.3 (± 19.2), p = 0.045 
(Table IV). However, the high values of ODI in three pa-
tients were not directly related to the episodes of SRBD.
Group 2 — patients on rhGH treatment
Seventeen patients: seven girls and ten boys, mean age 
8.8 years (± 5.1), genotype: deletion of chromosome 
15q11-13 in 12 patients, uniparental disomy in four 
patients, unbalanced chromosomal translocation be-
tween chromosome 15 and 21 with del 15q11-13 in one 
patient. Mean BMI SDS was 0.4 (± 1.1). rhGH therapy 
was continued for a mean time of four years, ± 3.0, 
mean rhGH dose was 0.019 mg/kg/day (± 0.006), IGF1 
SDS 1.0 (± 0.9) (16 pts). The values of PSG were: AHI 9.0 
(± 6.5), AI 6.5 (± 5.7), HI 2.5 (± 1.6) (Table II). CA was 
3.1 (± 4.4), while OSA was 2.5 (± 2.0) and mixed apnoea 
index was 0.9 (± 0.8) (Table III). Comparison with Group 
1 revealed no significant differences in the PSG values. 
Mean ODI was lower than in Group 1: 25.1 (± 17.4) 
vs. 36.3 (± 19.2), but did not reach the statistical sig-
nificance (p = 0.145). Interestingly, ODI together with 
mean time of apnoea was significantly lower than in 
Group 1a: ODI 25.1 vs. 60.9, p = 0.001 and mean time 
of apnoea 12 s vs. 10.2 s, p = 0.036 (Table II, IV). 
In three patients with high IGF1 levels AHI was 
scored as moderate to severe (6.3–14.3). Only one pa-
tient with high IGF1 value had adenoid hypertrophy. 
Group 3 — patients without rhGH therapy due 
to severe obesity
Eight patients, four girls and four boys, mean age 13.1 
yrs (± 4.4), genotype: deletion of chromosome 15q11-13 
in six patients, uniparental disomy in two patients. All 
patients were severely obese, mean BMI SDS 5.3 (± 1.3). 
The values of PSG were: AHI 8.2 (± 5.4), AI 3.4 (± 2.2), 
and HI 4.8 (± 3.5) (Table II). OSA was 2.0 (± 1.7), while 
Table I. Clinical characteristics of PWS patients
Tabela I. Charakterystyka kliniczna pacjentów PWS
Group of 
PWS pts
1 1a 2 3
Number of 
pts
11 6 17 8
Age 3.0 (± 3.0) 2.5 (± 0.8) 8.8 (± 5.1) 13.1 (± 4.4)
BMI SD 0.2 (± 2.3) –0.1 (± 2.3) 0.4 (± 1.1) 5.3 (± 1.3)
IGF1 SD –0.9 (± 0.4) 0.2 (± 1.2) 1.0 (± 0.9) —
Tonsillar 
hypertrophy
2 None 4 3
Scoliosis 1 1 6 2
Group 1 — before rhGH therapy; Group 1a — after start of rhGH therapy in  
a mean time of 0.9 years; Group 2 — on rhGH treatment for a mean time  
of 4 years; Group 3 — without rhGH therapy
Table II. Type of sleep-related breathing disorders in PWS 
patients
Tabela II. Charakterystyka zaburzeń oddychania w czasie 
snu u pacjentów PWS
Group of 
PWS pts
1 1a 2 3
AHI 10.2 (± 6.9) 12.0 (± 5.8) 9.0 (± 6.5) 8.2 (± 5.4)
AI 6 (± 4.5) 9.1 (± 4.7) 6.5 (± 5.7) 3.4 (± 2.2)
HI 4.2 (± 2.9) 2.9 (± 2.5) 2.5 (± 1.6) 4.8 (± 3.5)
Mean time 
of apnoea 
[sec]
11.2 (± 6.6) 10.2 (± 1.2) 12 (± 1.9) 12.1 (± 2.6)
Max time 
of apnoea 
[sec]
28 (± 17.8) 23.7 (± 
12.4)
27.9 (± 8.6) 29.4 (± 18.3)
AHI — apnoea-hypopnoea index correlated with desaturation; AI — apnoea 
index correlated with desaturation; HI — hypopnoea index correlated with 
desaturation; Group 1— before rhGH therapy; Group 1a — after start of rhGH 
therapy in a mean time of 0.9 years; Group 2 — on rhGH treatment for a mean 
time of 4 years; Group 3 — without rhGH therapy
Table III. Type of apnoea
Tabela III. Rodzaje bezdechów
Group of 
PWS pts
1 1a 2 3
CA 2.4 (± 3.1) 4.8 (± 2.9) 3.1 (± 4.4) 0.9 (± 0.5)
OSA 2.3 (± 1.2) 2.7 (± 1.7) 2.5 (± 2.0) 2.0 (± 1.7)
Mixed 
apnoea 
index
1.3 (± 1.2) 1.6 (± 1.8) 0.9 (± 0.8) 0.4 (± 
0.3)
CA — central apnoea index; OSA — obstructive sleep apnoea index; Group 1 
— before rhGH therapy; Group 1a — after start of rhGH therapy in a mean time 
of 0.9 years; Group 2 — on rhGH treatment for a mean time of 4 years; Group 
3 — without rhGH therapy
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CA was 0.9 (± 0.5), and mixed apnoea index 0.4 (± 0.3) 
(Table III). Mean ODI was 22.0 (± 13), other values of 
desaturation are shown in Table IV. Comparison with 
Group 2 revealed significantly higher values of mean HI: 
4.8 vs. 2.5, p = 0.032 and longer mean desaturation time: 
17.8 vs. 14.3, p = 0.043. Comparing the results to Group 
1a revealed for the first time in the study a significant 
difference in the results of AI. Interestingly, the AI was 
significantly lower in the obese patients: 3.4 vs. 9.1, p = 
0.01. Moreover, we found lower values of CA 0.9 vs. 4.8, 
p = 0.002 and mean ODI: 22.0 vs. 60.9, p = 0.005 and 
higher both mean and max desaturation values (91.4 
vs. 85.7% and 66.6 vs. 61.5%, p = 0.008 and p = 0.005, 
respectively). However, the mean time of desaturation 
was longer in the obese children (17.8 vs. 12.3 s, p = 0.01).
Comparing the results to the children before the 
GH treatment showed only longer mean desaturation 
time: 17.8 s vs. 14.4 s (p = 0.02). 
Results — all groups of patients 
Moderate SRBD with AHI > 5 was diagnosed in 9 out 
of 10 in Group 1, in all patients in Group 1a, in 12 out of 
17 patients in Group 2, and in 6 out of 9 in Group 3. 
Severe type SRBD with AHI > 10 was most commonly 
present in Group 2. The patients in Group 2 and 3 were 
much older than in Group 1; therefore, the clinical 
picture of the disease differed between these groups.
Interestingly, AHI did not differ significantly be-
tween the patients before and after initiation of rhGH 
as well as between the groups on rhGH therapy and 
untreated severely obese patients. 
CA dominated in Group 1a and was significantly 
higher than in Group 3. There were no significant dif-
ferences in OSA between Group 1 and 1a (Table III). 
These results do not validate the hypothesis that the 
initiation of rhGH causes worsening of OSA by growth 
of lymphoid tissue due to the rise in IGF1. The ODI 
value was significantly higher in Group 1a than in all 
other groups, but was not strictly related to SRBD. The 
mean saturation was below the minimal normal value 
in groups treated with rhGH, reaching statistical sig-
nificance between the Group 1a and 3 (88% vs. 93.1%, 
p = 0.037) (Table IV). 
Analysis of the PSG data in relation to laryngeal 
history revealed significantly higher HI in the patients 
with adenoid enlargement (2.8 vs. 5.6, p = 0.007). 
The PSG results in relation to orthopaedic history 
showed lower mean saturation values in patients with 
scoliosis (88 vs. 92%, p = 0.026). 
Further analysis of the group of patients treated with 
rhGH for a longer time unexpectedly showed a posi-
tive correlation between the time of rhGH therapy and 
AHI, AI, CA, both mean time of apnoea and hypopnea, 
as well as mean desaturation value. The only negative 
correlation applied to the mean time of desaturation. 
We observed a positive correlation between the IGF1 
SDS values and both OSA and HI. 
Discussion
SRBD were present in almost all PWS patients, mostly 
scored as moderate to severe. According to the results 
of our study the saturation values seem to deteriorate 
after short-term GH therapy with significantly higher 
ODI, but without differences in AHI and other PSG 
values. The results in the group treated with GH for 
a longer period do not differ significantly from the 
group before the rhGH therapy. However, there is 
a wide range of the patients’ age, and therefore the 
data are difficult to interpret due to different clinical 
characteristics. 
SRBD are part of the PWS characteristics [23]. Few 
papers are related to SRBD in relation to GH adminis-
tration in PWS patients. A study by Haqq et al. showed 
a decreased AI and HI in 12 PWS patients after six 
months of rhGH treatment, but this trend was not 
statistically significant [5]. 
Another paper, by Festen et al., showed no signifi-
cant difference in the PSG performed before and after 
six months of rhGH treatment in 35 PWS patients [6].
Miller et al. reported results of 25 PWS patients 
(16 children) after six weeks of rhGH therapy, with 
improvement of AHI in 14 patients, but worsening of 
obstructive events in six patients. Among them four 
had upper respiratory tract infections or adenotonsillar 
Table IV. Desaturation characteristics
Tabela IV. Charakterystyka desaturacji
Group of 
PWS pts
1 1a 2 3
ODI 36.3 (± 19.2) 60.9 (± 25.4) 25.1 (± 17.4) 22.0 (± 13)
Mean 
desaturation 
[%]
88.6 (± 3.5) 85.7% (± 4.7) 89.3 (± 3.6) 91.4 (± 1.8)
Max 
desaturation 
[%]
65.8 (± 6.3) 61.5 (± 1.1) 65.0 (± 7.3) 66.6 (± 3.5)
Mean 
desaturation 
time [sec]
14.4 (± 2.2) 12.3 (± 2.7) 14.3 (± 3.8) 17.8 (± 3.6)
Max 
desaturation 
time [min]
1.3 (± 0.7) 1.1 (± 0.2) 1.3 (± 0.4) 1.4 (± 0.6) 
Mean 
saturation 
[%]
91.8 (± 1.9) 88 (± 5.7) 90 (± 6.4) 93.1 (± 2.2)
ODI — oxygen desaturation index; Group 1— before rhGH therapy; Group 1a 
— after start of rhGH therapy in a mean time of 0.9 years; Group 2 — on rhGH 
treatment for a mean time of 4 years; Group 3 — without rhGH therapy
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hypertrophy, with elevated IGF1 level in two patients 
[9]. In our study, the patients with high IGF1 levels had 
moderate to severe SRBD. 
Williams et al. reported 37 PWS patients, both 
children and young adults, specifically selected for 
SRBD, some on rhGH treatment, with no significant 
differences between the group treated with rhGH and 
non-treated patients [24].
Those results are similar to our studies, as we did 
not find the statistical differences between AHI values 
in relation to rhGH treatment. Moreover, the worsening 
of ODI found in our group of short-term rhGH therapy 
was not strictly related to SRBD.
Consensus guidelines for rhGH therapy in PWS, pub-
lished in JCEM 2013, include the need for close monitor-
ing of any changes in breathing, particularly in sleep, and 
evaluation by oximetry or polysomnography, together 
with ENT assessment, within the first three to six months 
of the rhGH treatment [25]. It states that longer rhGH 
therapy causes improvement in respiratory muscle func-
tion [5, 9, 25]. However, the influence of rhGH on central 
respiratory drive is difficult to interpret [25–27].
Conclusions
Our study confirms the high frequency of SRBD among 
PWS patients, mostly of moderate or severe type. Ac-
cording to the results of polygraphy studies, only the 
desaturation index seems to deteriorate after short-term 
rhGH therapy. The results in the group treated with 
rhGH for a longer period do not differ significantly 
from the group before the rhGH treatment. The main 
differences between the children treated for a longer 
period and the obese untreated patients were higher 
values of hypopnoea index and longer mean desatura-
tion time in the obese children. In conclusion, the results 
do not show a simple dependence between the SRBD 
and the period of rhGH therapy. It seems reasonable 
to perform sleep studies in all PWS patients, especially 
after initiating rhGH therapy.
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